Steven Limentani

7.8k total citations · 2 hit papers
60 papers, 3.4k citations indexed

About

Steven Limentani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Steven Limentani has authored 60 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 13 papers in Hematology. Recurrent topics in Steven Limentani's work include Lung Cancer Treatments and Mutations (18 papers), HER2/EGFR in Cancer Research (17 papers) and Cancer Treatment and Pharmacology (15 papers). Steven Limentani is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), HER2/EGFR in Cancer Research (17 papers) and Cancer Treatment and Pharmacology (15 papers). Steven Limentani collaborates with scholars based in United States, France and Belgium. Steven Limentani's co-authors include Paul G. Richardson, David Irwin, James R. Berenson, Melissa Alsina, Kenneth C. Anderson, Raymond Alexanian, Sundar Jagannath, David S. Siegel, Bart Barlogie and Rubén Niesvizky and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Steven Limentani

59 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

2004 569 citations Sundar Jagannath, Bart Barlogie et al. British Journal of Haematology profile →
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

2010 568 citations Steven Limentani et al. profile →

Peers

Countries citing papers authored by Steven Limentani

Since Specialization

Citations

This map shows the geographic impact of Steven Limentani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Limentani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Limentani more than expected).

Fields of papers citing papers by Steven Limentani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Limentani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Limentani. The network helps show where Steven Limentani may publish in the future.

Co-authorship network of co-authors of Steven Limentani

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Limentani. A scholar is included among the top collaborators of Steven Limentani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Limentani. Steven Limentani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE 2022 ·npj Breast Cancer ·Sibylle Loibl, Chiun‐Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean‐Christophe Théry, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lübbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark	22
2	96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE 2020 ·Annals of Oncology ·Sibylle Loibl, Chiun‐Sheng Huang, Max S. Mano, (unknown), Charles E. Geyer, Michael Untch, Gϋnter von Minckwitz, (unknown), Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lübbe, (unknown), Thomas Hatschek, David Tesarowski, Thomas Boulet, Claudia Wiese, Cailu Song, Norman Wolmark	18
3	Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial 2017 ·Journal of Surgical Oncology ·Harry D. Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani, Richard L. White, (unknown), Judith O. Hopkins, (unknown), Angel Rodriguez, Amy P. Sing	70
4	Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study 2016 ·Annals of Oncology ·(unknown), P. Fumoleau, J A Dewar, Joan Albanell, Steven Limentani, Mario Campone, Jenny C. Chang, Monika Patre, Alexander Strasak, Sanne Lysbet de Haas, Jin Xu, José Á. García-Sáenz	45
5	Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9 2015 ·Breast Cancer Research and Treatment ·Jame Abraham, André Robidoux, Antoinette R. Tan, Steven Limentani, Keren Sturtz, (unknown), (unknown), Marc Buyse, Norman Wolmark, Samuel A. Jacobs	19
6	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study 2015 ·The Breast ·Véronique Dièras, Hans Wildiers, Jacek Jassem, Luc Dirix, Jean‐Paul Guastalla, Petri Bono, Sara A. Hurvitz, Anthony Gonçalvès, Gilles Romieu, Steven Limentani, Guy Jérusalem, K C Lakshmaiah, Henri Roché, Pedro Sánchez‐Rovira, Tadeusz Pieńkowski, Miguel Ángel Seguí, Li Ai, Yu‐Nien Sun, Cheryl A. Pickett, Dennis J. Slamon	40
7	Abstract P4-12-07: Neoadjuvant trastuzumab emtansine and docetaxel, with or without pertuzumab, in patients with HER2-positive early-stage breast cancer: Results from a phase 1b/2a study 2013 ·Cancer Research ·Miguel Martín, J A Dewar, (unknown), Steven Limentani, (unknown), Alexander Strasak, Monika Patre, (unknown)	2
8	Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study 2013 ·Cancer Chemotherapy and Pharmacology ·Rachel C. Jankowitz, Jame Abraham, Antoinette R. Tan, Steven Limentani, (unknown), (unknown), Marc Buyse, Norman Wolmark, Samuel A. Jacobs	49
9	Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer 2008 ·Journal of Thoracic Oncology ·Frank C. Detterbeck, Mark A. Socinski, Richard J. Gralla, Martin J. Edelman, Thierry Jahan, David Loesch, Steven Limentani, Ramaswamy Govindan, Muhammad Zaman, Zhishen Ye, Matthew Monberg, Coleman K. Obasaju	21
10	Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma 2008 ·British Journal of Haematology ·Sundar Jagannath, Bart Barlogie, James R. Berenson, David S. Siegel, David Irwin, Paul G. Richardson, Rubén Niesvizky, Raymond Alexanian, Steven Limentani, Melissa Alsina, Dixie‐Lee Esseltine, Kenneth C. Anderson	75
11	Efficacy and Safety of Single-Agent Axitinib (AG-013736; AG) in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Phase II Trial 2007 ·Clinical Lung Cancer ·Joan H. Schiller, Joachim von Pawel, Timothy Larson, S-H.I. Ou, Steven Limentani, Alan B. Sandler, Everett E. Vokes, (unknown), Katherine Liau, Paul Bycott	1
12	Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study 2006 ·British Journal of Cancer ·A. William Blackstock, F. Mornex, Christian Partensky, L Descos, L. Douglas Case, Susan A. Melin, Edward A. Levine, (unknown), Steven Limentani, Lisa A. Kachnic, Joel E. Tepper	23
13	Phase II Study of Neoadjuvant Docetaxel/Vinorelbine Followed by Surgery and Adjuvant Doxorubicin/Cyclophosphamide in Women with Stage II/III Breast Cancer 2006 ·Clinical Breast Cancer ·Steven Limentani, Adam Brufsky, John K. Erban, (unknown), Deborah Lewis	6
14	Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer 2005 ·Annals of Oncology ·William J. Gradishar, Suparna Wedam, Mohammad Jahanzeb, John K. Erban, Steven Limentani, (unknown), Steven R. Olsen, Sandra M. Swain	32
15	A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme 2005 ·Journal of Neuro-Oncology ·Steven Limentani, Anthony L. Asher, (unknown), Joseph W. Kim, Robert Fraser	39
16	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma 2005 ·Cancer ·James R. Berenson, Sundar Jagannath, Bart Barlogie, David Siegel, Raymond Alexanian, Paul G. Richardson, David Irwin, Melissa Alsina, S. Vincent Rajkumar, (unknown), Seema Singhal, Steven Limentani, Rubén Niesvizky, Dixie Esseltine, Elizabeth Trehu, David P. Schenkein, Kenneth C. Anderson	82
17	A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma breakdown → 2004 ·British Journal of Haematology ·Sundar Jagannath, Bart Barlogie, James R. Berenson, David S. Siegel, David Irwin, Paul G. Richardson, Rubén Niesvizky, Raymond Alexanian, Steven Limentani, Melissa Alsina, Julian Adams, Michael Kauffman, Dixie‐Lee Esseltine, David P. Schenkein, Kenneth C. Anderson	569
18	High-Purity Factor IX Concentrates for Treatment of Hemophilia B: Relative Purity and Thrombogenic Potential 1995 ·Acta Haematologica ·Steven Limentani, (unknown), Steven R. Deitcher	17
19	Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies 1994 ·Blood Coagulation & Fibrinolysis ·Steven Limentani	2
20	Recombinant Blood Clotting Proteins for Hemophilia Therapy 1993 ·Seminars in Thrombosis and Hemostasis ·Steven Limentani, David A. Roth, Barbara C. Furie, Bruce Furie	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact